相关实验视频

Updated: Jun 29, 2025

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

埃夫加尔提吉莫德用于治疗吉-巴雷综合征

Huiqiu Zhang^1,2, Jing Ma^1,2, Yingna Feng¹

¹Department of Neurology, First Hospital, Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.

Journal of neurology

|March 27, 2024

概括

埃夫加尔蒂基莫德在吉兰-巴雷综合征 (GBS) 治疗方面表现有前途. 两剂剂量迅速改善了GBS患者的肌肉强度,具有良好的安全性,表明其作为新疗法的潜力.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

吉兰-巴雷综合征 (GBS) 是一种由免疫球蛋白G (IgG) 自体抗体引发的自身免疫性疾病.
针对新生儿Fc受体 (FcRn) 的Fc片段Efgartigimod可以增强IgG降解.
这种机制表明efgartigimod在GBS中的潜在治疗价值.

研究的目的:

评估efgartigimod在Guillain-Barré综合征患者中的疗效和安全性.
评估efgartigimod对肌肉力量恢复和GBS的不良事件的影响.

主要方法:

两名GBS患者呈现急性性,在五天内接受了两剂efgartigimod (10 mg/kg) 治疗.
进行了神经传导研究以确认外围神经病变.
监测了患者的结果,包括肌肉强度,运动能力和不良事件.

主要成果:

两位患者的肌肉强度都显著改善,在四周内能够独立行走.
一名患者报告过渡性肌肉疼痛;另一个患者因呼吸衰竭需要输管治疗,但没有报告其他不良影响.
在这些GBS病例中,efgartigimod显示出令人满意的安全性.

结论:

在GBS患者中,efgartigimod有效且快速改善肌肉力量.
这些发现支持efgartigimod作为GBS新治疗方法的潜力.
需要进一步的精心设计的临床试验来证实这些结果.

关键词:

在Efgartigimod中使用.这是一种FcRn抑制剂.吉兰·巴雷综合征吉兰·巴雷综合征在IgG IgG的基础上.

更多相关视频

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...